Teva's UZEDY shows lower emergency visits and healthcare costs versus rival schizophrenia treatments in real-world study

The Quick Take

• Real-world data shows UZEDY kept schizophrenia patients on treatment longer than competing long-acting injectable drugs
• Patients on UZEDY had fewer emergency room visits and hospitalizations compared to other schizophrenia treatments
• Overall healthcare costs were lower for UZEDY patients, strengthening the economic case for broader formulary coverage

Real-world evidence studies are increasingly decisive in the US psychiatric pharmaceutical market, where payer coverage decisions hinge on demonstrated outcomes beyond controlled clinical trials. UZEDY is Teva's subcutaneous long-acting injectable risperidone formulation approved by the FDA in 2023, designed to improve medication adherence in schizophrenia patients who struggle with oral dosing compliance. Teva's presentation of real-world cost and hospitalization data follows a standard specialty pharma playbook: convert clinical efficacy into health economics evidence to unlock formulary tier improvements with payers.

If these findings support broader insurer formulary inclusion, UZEDY can materially lift Teva's branded specialty revenue, which has been a strategic priority to offset pricing pressure on its generic drug portfolio. Key US competitors in the long-acting injectable schizophrenia market include Johnson and Johnson's Invega Sustenna and Trinza, Alkermes' Aristada, and Otsuka's Abilify Maintena. A cost-savings narrative resonates particularly with Medicaid managed care organizations, which cover the majority of US schizophrenia treatment costs and are under sustained budget pressure.

Watch Teva's Q3 2026 earnings call for UZEDY net revenue progression and any disclosed formulary wins with major PBMs or Medicaid MCOs. Any FDA label update expanding UZEDY's approved patient population would be a direct commercial catalyst. The macro variable is US Medicaid budget dynamics: federal budget negotiations could either accelerate adoption of cost-effective LAI formulations as a managed care priority, or impose drug price caps that compress branded pharmaceutical margins across Teva's specialty portfolio.

Synthesized from 1 source.